Table 6.
Full multivariate analysis for first skeletal-related event
| Variable | RR | (95% CI) | p value |
|---|---|---|---|
| Age ≥ 50 years | 1.12 | (0.69, 1.83) | 0.651 |
| ECOG performance status | |||
| 2 – 3 versus 0 – 1 | 1.33 | (0.78, 2.25) | 0.296 |
| Hydroxyproline/Creatinine ratio (centered) | 0.97 | (0.92, 1.03) | 0.292 |
| Bone-specific alkaline phosphatase, U/L | 1.01 | (1.00, 1.02) | 0.083 |
| Estrogen-receptor status versus negative | |||
| Positive | 0.94 | (0.50, 1.76) | 0.838 |
| Unknown | 0.91 | (0.35, 2.36) | 0.844 |
| Progesterone-receptor status versus negative | |||
| Positive | 0.80 | (0.41, 1.55) | 0.506 |
| Unknown | 1.19 | (0.51, 2.81) | 0.685 |
| Sites of metastasis (yes versus no) | |||
| Bone as only metastatic site | 0.81 | (0.45, 1.44) | 0.467 |
| Lung | 1.49 | (0.70, 3.20) | 0.306 |
| Liver | 0.98 | (0.48, 1.99) | 0.960 |
| Time from diagnosis of bone metastases to study entry, years | 1.01 | (0.84, 1.20) | 0.992 |
| Time from cancer diagnosis to study entry, years | 0.97 | (0.91, 1.04) | 0.395 |
| Lesion characteristics and numbers | |||
| ≥ 3 osteolytic versus < 3 osteolytic | 1.53 | (0.96, 2.44) | 0.071 |
| 1 – 2 osteoblastic versus no osteoblastic | 1.70 | (1.01, 2.86) | 0.045 |
| ≥ 3 osteoblastic versus no osteoblastic | 0.70 | (0.24, 2.08) | 0.525 |
| 1 – 2 mixed versus no mixed | 1.16 | (0.57, 2.33) | 0.687 |
| ≥ 3 mixed versus no mixed | 1.47 | (0.72, 3.01) | 0.291 |
| Prior fracture (yes versus no) | 0.83 | (0.44, 1.58) | 0.577 |
| Pain scores (centered) | 1.27 | (1.15, 1.40) | < 0.001 |
| Prior chemotherapy (yes versus no) | 1.07 | (0.33, 3.41) | 0.915 |
| ≥ 2 prior hormonal therapies (yes versus no) | 1.00 | (0.62, 1.62) | 1.000 |
| Prior radiotherapy (yes versus no) | 1.84 | (1.11, 5.03) | 0.018 |
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.